Intertriginous eruption associated with chemotherapy in pediatric patients

Archives of Dermatology

Volumn 143, Issue 1, 2007, Pages 67-71

  Webber, Kathryn A ^a   Kos, Liborka ^a   Holland, Kristen E ^a   Margolis, David A ^a   Drolet, Beth A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; RAZOXANE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CHEMOTHERAPY; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; SKIN MANIFESTATION;

ABDOMEN; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARM; AXILLA; CHILD; CHILD, PRESCHOOL; DRUG ERUPTIONS; FEMALE; GROIN; HEART NEOPLASMS; HEMANGIOSARCOMA; HUMANS; INFANT; INTERTRIGO; MALE; NEUROBLASTOMA; RETROSPECTIVE STUDIES; THORAX;

EID: 33846449543     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.1.67     Document Type: Article

References (17)

1. Wenzel FG, Horn TD. Nonneoplastic disorders of the eccrine glands. J Am Acad Dermatol. 1998;38:1-17.
2. Horn TD. Antineoplastic chemotherapy, sweat, and the skin. Arch Dermatol. 1997;133:905-906.
3. Horn TD, Beveridge RA, Egorin MJ, Abeloff MD, Hood AF. Observations and proposed mechanism of N,N′,N″-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation. Arch Dermatol. 1989;125:524-527.
4. Pierson JC, Helm TN, Taylor JS, et al. Neutrophilic eccrine hidradenitis heralding the onset of acute myelogenous leukemia. Arch Dermatol. 1993;129:791-792.
5. Smith KJ, Skelton HG, James WD, et al. Neutrophilic eccrine hidradenitis in HIV-infected patients. J Am Acad Dermatol. 1990;23:945-947.
6. Stahr RJ, Cooper PH, Caputo RV. Idiopathic plantar hidradenitis: a neutrophilic eccrine hidradenitis occurring primarily in children. J Cutan Pathol. 1994;21:289-296.
7. Bachmeyer C, Aractingi S. Neutrophilic eccrine hidradenitis. Clin Dermatol. 2000;18:319-330.
8. Greenbaum BH, Heymann WR, Reid CS, Travis SF, Donaldson MH. Chemotherapy-associated eccrine hidradenitis: neutrophilic eccrine hidradenitis reevaluated: the role of neutrophilic infiltration. Med Pediatr Oncol. 1988;16:351-355.
9. Serrano T, Saez A, Moreno A. Eccrine squamous syringometaplasia: a prospective clinicopathologic study. J Cutan Pathol. 1993;20:61-65.
10. Lerner TH, Barr RJ, Dolezal JF, Stagnone JJ. Syringomatous hyperplasia and eccrine squamous syringometaplasia associated with benoxaprofen therapy. Arch Dermatol. 1987;123:1202-1204.
11. Valks R, Fraga J, Porras-Luque J, et al. Chemotherapy-induced eccrine squamous syringometaplasia: a distinctive eruption in patients receiving hematopoietic progenitor cells. Arch Dermatol. 1997;133:873-878.
12. Prussick R, Horn TD, Wilson WH, Turner MC. A characteristic eruption associated with ifosfamide, carboplatin, and etoposide chemotherapy after pretreatment with recombinant interleukin-1 alpha. J Am Acad Dermatol. 1996;35:705-709.
13. Hurt MA, Halvorson RD, Petr C, Cooper JT, Friedman DJ. Eccrine squamous syringometaplasia: a cutaneous sweat gland reaction in the histologic spectrum of "chemotherapy-associated eccrine hidradenitis" and "neutrophilic eccrine hidradenitis." Arch Dermatol. 1990;126:73-77.
14. English JC, Toney R, Patterson JW. Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin. J Cutan Pathol. 2003;30:591-595.
15. Criley P, Topolsky MJ, Styler MJ, et al. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:361-365.
16. Prussick R. Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy. Semin Cutan Med Surg. 1996;15:267-276.
17. Horn TD, Redd JV, Karp JE, et al. The cutaneous eruption of lymphocyte recovery. Arch Dermatol. 1989;125:1512-1517.